Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diammonium glycyrrhizinate for treatment of COVID-19
ChiCTR2200058045Phase 3Not yet recruiting
- Sponsor
- National Institute of Public Health
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of glycyrrhizin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by National Institute of Public Health. Primary endpoints: Lung CT evaluation at month 6, Improvement of clinical symptoms at month 6 and 1 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
glycyrrhizin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200058045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058045.